Q BIOMED VISION

Q BioMed (QBIO) aims to accelerate the monetization of biomedical technologies through rapid innovation and collaborative partnerships
with industry leading researchers. Q BioMed believes its assets in oncology, vascular disease, and rare orphan diseases address unmet
medical needs and large markets. The Company’s FDA approved, non-opioid drug Metastron, which relieves cancer bone pain, is expected
to begin generating revenues in 2019. Metastron is also approved for sale in 21 other countries. In addition to treating pain, Metastron has
shown evidence of treating the cancer itself and extending survival. Q BioMed plans to conduct Phase IV trials to support label extension
and cancer survival benefit using Metastron. The Company’s robust clinical pipeline is expected to produce growing revenues for the
Company and value infection points for investors.

 



Investor Presentation
QBIO Corporate Website
QBIO Corporate News

Q BioMed’s Industry-Changing Diagnostic Kit To Serve Unmet Need for 70 Million Glaucoma Sufferers

NEW YORK, NY / ACCESSWIRE / March 21, 2019 / Q BioMed (QBIO) and its key technology partners are set to initiate development of an industry-changing diagnostic kit for monitoring glaucoma severity and progression. Pending FDA clearance, which could come sooner than many biotech investors might expect, this kit offers the potential to improve the quality of life for glaucoma sufferers by helping preserve visual function in glaucoma patients through accurate monitoring of disease progression. As a result, this diagnostic offers substantial future value to the Company.

Diagnostic Kit Offers Critical, First-of-its-Kind Functionality

Based on the novel GDF15 biomarker, this kit’s core, platform technology enables more effective measurement and management of glaucoma progression and patient treatment than any current monitoring or therapeutic approaches—a tremendous advantage. Considering that no single examination or diagnostic test is able to accurately predict disease progression, QBIO’s prospective offering serves an unmet need for millions of patients.

Glaucoma, which afflicts 70 million people, is diagnosed via a comprehensive eye exam, including visual field testing and tonometry, which measures pressure inside the eye as a means to determine if increased risk factors for glaucoma exist. While this may be the gold standard in intraocular therapy testing, this method is not truly counted on for diagnostic purposes as it relates to determining progression. As a result, the GDF15-based tool could emerge as the industry’s diagnostic standard-bearer and early stage detector.

The Next Steps

This enabling technology will act as a companion diagnostic to the MAN-01 small molecule therapeutic with a novel mechanism of action for the treatment of Primary Open-Angle Glaucoma. The aim is to develop a simple integrated diagnostic test that can be performed at a physician’s office with no external, expensive equipment.

The Biointerfaces Institute will work with Mannin Research to create, assess, and apply DNA aptamers for detecting GDF15 in aqueous humor of patients with different severities of glaucoma. The intent is to create multiple prototype assays for the detection of GDF15 which will be suitable for point-of-care testing. Thus, the prototype kits are to be validated in a clinical setting. This personalized medicine approach illustrates the underlying innovation of the platform technology whose key function is to improve disease progression measurement and patient treatment outcomes.

Interestingly, the Company has a good deal of flexibility with respect to its development process and FDA clearance pathway. It can elect to develop the kit for 510(k) FDA clearance or a PMA (Premarket Approval) designation and each pathway has its own advantages. It has been our experience that the 510(k) process tends to be faster than PMA, which means that revenue could be generated very quickly. The PMA route, while a bit longer, can sometimes provide a greater marketing and deployment boost as the underlying providers can advertise their device as PMA-approved or FDA-approved.

Major Value to Be Generated Via the QBIO Roadmap

The QBIO product roadmap provides key insight into the business model from which investors can extrapolate a future, tangible value range.

Diagnostic

Upon clearance or approval of the diagnostic kit, Q BioMed would charge a to-be-determined fee to the ophthalmologist for each assay and analysis. Since glaucoma is a lifelong disease, these swift tests will have to be performed on a routine basis on patients to preserve visual acuity and measure progression, it renders the kit as a recurring (and compounding) revenue stream for the physician and the Company. Considering 70 million are afflicted today, and millions more could be tested for measurement and progression at earlier intervals, it is reasonable to expect that one in three patients could regularly undergo this test, generating considerable revenue.

Therapeutic

Leveraging a novel mechanism of action, this platform technology will act as a companion diagnostic to the MAN-01 small molecule therapeutic which Q BioMed and Mannin Research Inc. are currently developing to treat Primary Open-Angle Glaucoma. By serving as a companion diagnostic to the therapeutic, the device will play the role of a bridge from diagnosis/analysis/monitoring to therapeutic treatment—which could carry a price tag far greater than that of the diagnostic kit. In essence, by capturing a meaningful share of the diagnostic market for this segment due to the one-of-a-kind properties and capabilities, the migration to the higher priced and higher profit therapeutic could be considered a slam dunk.

QBIO DISCLAIMER

This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by MEC Systems LLC is a wholly owned subsidiary of milestonecgp.com, milestonecapitolgrowthportfolio.com 

Any wording found in this e-mail, disclaimer or company profile referencing to “I” or “we” or “our” or “MEC Systems LLC” refers to MEC Systems LLC.  Our business model is to be financially compensated to market and promote small public companies.  By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.

We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our profiles, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. We have been compensated $5,000k cash via bank wire by cream Edm media llc;  ,  to conduct Social Media Program and news distribution for QBIO from 3/22/2019 to 3/29/2019 .  MEC Systems LLC business model is to receive financial compensation to advertise for public companies.  This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only.  We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates may wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices.  Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.

We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MEC Systems LLC often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. See full disclaimer at http://milestonecapitalgrowthportfolio.com/terms-conditions-of-use/.